PSMA-Binding Agents for Prostate Cancer Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular imaging methods for prostate cancer are ineffective due to the low metabolism and small size of the prostate gland, leading to poor detection and limited therapeutic options.
Innovation Solution
Development of radioisotope labeled prostate-specific membrane antigen (PSMA) binding compounds that offer improved tissue-specificity and contrast between target and non-target tissues, enabling more accurate imaging and potential therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional molecular imaging methods are used for prostate cancer, then imaging is possible, but detection accuracy is poor due to low metabolism and small size of the prostate gland
Solution Approach 1:
The patent changes the biochemical parameters of the imaging agent by selecting compounds that bind to PSMA, a protein overexpressed on prostate cancer cells. This allows the imaging agent to accumulate specifically in prostate cancer tissue despite the organ's low metabolism and small size, thereby improving detection accuracy
Solution Approach 2:
The patent introduces PSMA-binding compounds as an intermediary mechanism to overcome the direct limitations of prostate gland size and metabolism. These compounds serve as mediators that selectively accumulate in prostate cancer tissue, enabling accurate imaging without being constrained by the organ's physiological characteristics
2Reliability
If radiopharmaceuticals are excreted into the urinary bladder, then elimination from the body occurs, but contrast between target and non-target tissues is reduced
Solution Approach 1:
The patent applies local quality by designing imaging agents with selective affinity for PSMA-expressing tissues. The compounds concentrate specifically in prostate cancer cells while being excreted through the urinary bladder, creating high local contrast in target tissues while maintaining rapid clearance from non-target areas
Solution Approach 2:
The patent utilizes dynamic pharmacokinetics where the imaging agent exhibits selective accumulation in PSMA-positive tissues followed by rapid renal excretion. This dynamic behavior creates optimal contrast between target and non-target tissues at specific time points post-administration
3Adaptability or versatility
If existing radiopharmaceuticals are used for prostate cancer imaging, then imaging can be performed, but tumor-specific uptake is insufficient across all PCa phenotypes
Solution Approach 1:
The patent employs PSMA-binding compounds that demonstrate universal applicability across different prostate cancer phenotypes. Since PSMA is overexpressed on most solid tumor neovasculature and in prostate cancer, a single class of agents can target multiple cancer types and subtypes, providing versatile tumor-specific uptake
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed imaging agents provide enhanced specificity and contrast for prostate cancer imaging, allowing for better detection and monitoring of the disease, as well as potential therapeutic targeting of PSMA-expressing tissues.
Implementation Method 1
radioisotope labeled prostate specific membrane antigen (PSMA) binding compounds
Implementation Method 2
imaging methods using the radioisotope labeled compounds
Data Source
AI summary
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.